STARD3 and breast carcinoma: The survival analyses showed that STARD3+ patients did not have significantly different overall (HR 0.15 [95% CI = 0.01, 1.70]; p = 0.127), breast cancer-specific (HR = 0.05 [95% CI = 0.00, 2.54], p = 0.132), relapse-free (HR 0.63 [95% CI = 0.12, 3.41]; p = 0.59), and distant metastasis-free (HR 0.48 [95% CI = 0.08, 2.79]; p = 0.41) survivals than STARD3 patients, and this was independent to the adjustment parameters.